Indications for cytoreductive surgery plus HIPEC in patients with colorectal cancer and peritoneal metastasis.

Document Type : Research/Original Article

Authors

1 Asian School of Peritoneal Surface Malignancy Treatment, Kyoto City, Kyoto Prefecture, Japan.

2 Department of Regional Cancer Therapy, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital, Kishiwada City, Oosaka Prefecture, Japan.

3 Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kusatsu General Hospital, Kusatsu City, Shiga Prefecture, Japan.

4 Department of Regional Cancer Therapy, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital, Kishiwada City, Oosaka Prefecture, Japan

5 Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kusatsu General Hospital, Kusatsu City, Shiga Prefecture, Japan

6 Department of Surgery, Mizonokuchi Hospital, Teikyo University, School of medicine, Kawasaki, Kanagawa, Japan.

10.30476/acrr.2023.98167.1172

Abstract

Abstract
Comprehensive treatment (COMPT) consisting of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with peritoneal metastasis (PM) from colorectal cancer (CRC). The aim of the present study was to clarify clinicopathologic parameters that are indications to perform COMPT in CRC-patients with CRC-PM.
Between 2006 and 2021, 447 patients were selected as eligible for COMPT among 906 CRC-patients with PM. Clinicopathologic parameters contributing to long-term survival and cure were analyzed.
Results: A log-rank test showed a significant survival difference for peritoneal cancer index (PCI) (≤12 vs. ≥13), completeness of cytoreduction (CCR) score (CCR-0 vs. CCR-1), small bowel (SB)-PCI (≤2 vs. ≥3), liver/lung metastasis (LLM) (negative vs. positive), histologic type (differentiated type vs. signet ring cell (SRC) subtype), number of involved peritoneal sectors (≤6 vs. ≥7), HIPEC (done vs. not done) and postoperative complication (grade 0, 1, or 2 vs. grade 3, 4, or 5).
Muti-variate analyses revealed that CCR score (CCR-0 vs. CCR-1), SB-PCI score (≤2 vs. ≥3), LLM (negative vs. positive), and HIPEC (performed vs. not done) were independent prognostic factors.
The incidence of postoperative grade 3, 4 or 5 complication was 19.0% (85/447) and the mortality rate was 2.0% (9/447).
One hundred and seventy patients fulfilled the following clinicopathologic factors,PCI ≤12, SB-PCI ≤2, number of involved peritoneal sectors ≤6, no LLM, differentiated histologic type and CCR-0. The MST of these patients was 5.5 years, and 5- and 10-year survival rates were 57.8% and 24.6%, respectively. Postoperative grade 3, 4, and 5 complications in these 170 patients occurred in 9 (5.3%), 15 (8.8%) and 1 (0.6%), respectively.
Cured patients were defined as those alive without recurrence more than 5 years after CRS. All of the cured patients underwent CCR-0 resection. The PCI and SB-PCI of these 23 patients were ≤12 and ≤2, respectively.

Keywords

References

1. Sung H, Ferlay J, Siegel RL,
Laversanne M, Soerjomataram I,
Jemal A, et al. Global Cancer Statistics
2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries. CA: a
cancer journal for clinicians. 2021;71
(3):209-49.
2. Koppe MJ, Boerman OC, Oyen
WJ, Bleichrodt RP. Peritoneal
carcinomatosis of colorectal origin:
incidence and current treatment
strategies. Annals of surgery.
2006;243 (2):212-22.
3. Franko J, Shi Q, Goldman CD, Pockaj
BA, Nelson GD, Goldberg RM, et al.
Treatment of colorectal peritoneal
carcinomatosis with systemic
chemotherapy: a pooled analysis of
north central cancer treatment group
phase III trials N9741 and N9841.
Journal of clinical oncology : official
journal of the American Society of
Clinical Oncology. 2012;30 (3):263-7.
4. Franko J, Shi Q, Meyers JP, Maughan
TS, Adams RA, Seymour MT, et al.
Prognosis of patients with peritoneal
metastatic colorectal cancer given
systemic therapy: an analysis
of individual patient data from
prospective randomised trials from
the Analysis and Research in Cancers
of the Digestive System (ARCAD)
database. The Lancet Oncology.
2016;17 (12):1709-19.
5. Klaver YL, Leenders BJ, Creemers
GJ, Rutten HJ, Verwaal VJ, Lemmens
VE, et al. Addition of biological
therapies to palliative chemotherapy
prolongs survival in patients
with peritoneal carcinomatosis of
colorectal origin. American journal of
clinical oncology. 2013;36 (2):157-61.
6. Sugarbaker PH. Peritonectomy
procedures. Annals of surgery.
1995;221 (1):29-42.
7. Sugarbaker PH, Jablonski KA.
Prognostic features of 51 colorectal
and 130 appendiceal cancer patients
with peritoneal carcinomatosis
treated by cytoreductive surgery and
intraperitoneal chemotherapy. Annals
of surgery. 1995;221 (2):124-32.
8. Witkamp AJ, de Bree E, Van Goethem
R, Zoetmulder FA. Rationale
and techniques of intra-operative
hyperthermic intraperitoneal
chemotherapy. Cancer treatment
reviews. 2001;27 (6):365-74.
9. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al.
Heated intra-operative intraperitoneal
oxaliplatin after complete resection
of peritoneal carcinomatosis:
pharmacokinetics and tissue
distribution. Annals of oncology
: official journal of the European
Society for Medical Oncology.
2002;13 (2):267-72.
10. Issels RD. Hyperthermia adds to
chemotherapy. European journal of
cancer (Oxford, England : 1990).
2008;44 (17):2546-54.
11. Verwaal VJ, van Ruth S, de Bree
E, van Sloothen GW, van Tinteren
H, Boot H, et al. Randomized trial
of cytoreduction and hyperthermic
intraperitoneal chemotherapy versus
systemic chemotherapy and palliative
surgery in patients with peritoneal
carcinomatosis of colorectal cancer.
Journal of clinical oncology : official
journal of the American Society
of Clinical Oncology. 2003;21
(20):3737-43.
12. Elias D, Blot F, El Otmany A, Antoun
S, Lasser P, Boige V, et al. Curative
treatment of peritoneal carcinomatosis
arising from colorectal cancer by
complete resection and intraperitoneal
chemotherapy. Cancer. 2001;92
(1):71-6.
13. Shen P, Hawksworth J, Lovato J,
Loggie BW, Geisinger KR, Fleming
RA, et al. Cytoreductive surgery
and intraperitoneal hyperthermic
chemotherapy with mitomycin C
for peritoneal carcinomatosis from
nonappendiceal colorectal carcinoma.
Annals of surgical oncology. 2004;11
(2):178-86.
14. Glehen O, Kwiatkowski F, Sugarbaker
PH, Elias D, Levine EA, De Simone M,
et al. Cytoreductive surgery combined
with perioperative intraperitoneal
chemotherapy for the management
of peritoneal carcinomatosis from
colorectal cancer: a multi-institutional
study. Journal of clinical oncology
: official journal of the American
Society of Clinical Oncology. 2004;22
(16):3284-92.
15. Verwaal VJ, van Ruth S, Witkamp A,
Boot H, van Slooten G, Zoetmulder
FA. Long-term survival of peritoneal
carcinomatosis of colorectal origin.
Annals of surgical oncology. 2005;12
(1):65-71.
16. Elias D, Lefevre JH, Chevalier J,
Brouquet A, Marchal F, Classe
JM, et al. Complete cytoreductive
surgery plus intraperitoneal
chemohyperthermia with oxaliplatin
for peritoneal carcinomatosis
of colorectal origin. Journal of
clinical oncology : official journal
of the American Society of Clinical
Oncology. 2009;27 (5):681-5.
17. Yonemura Y, Tsukiyama G, Miyata
R, Sako S, Endou Y, Hirano M, et
al. Indication of peritonectomy
for peritoneal dissemination.
Gan to kagaku ryoho Cancer &
chemotherapy. 2010;37 (12):2306-11.
18. Yonemura Y, Elnemr A, Endou Y,
Ishibashi H, Mizumoto A, Miura M,
et al. Surgical results of patients with
peritoneal carcinomatosis treated with
cytoreductive surgery using a new
technique named aqua dissection.
Gastroenterology research and
practice. 2012;2012:521487.
19. Sapareto SA, Dewey WC. Thermal
dose determination in cancer therapy.
International journal of radiation
oncology, biology, physics. 1984;10
(6):787-800.
20. Jacquet P, Sugarbaker PH. Clinical
research methodologies in diagnosis
and staging of patients with peritoneal
carcinomatosis. Cancer treatment and
research. 1996;82:359-74.
21. Dindo D, Demartines N, Clavien
PA. Classification of surgical
complications: a new proposal with
evaluation in a cohort of 6336 patients
and results of a survey. Annals of
surgery. 2004;240 (2):205-13.
22. Na t i o n a l C o m p r e h e n s i ve
Cancer Network.Colon Cancer
(version 1.2022) [cited 2022.
Available from: https://www.
nccn.org/guidelines/guidelinesdetail?
category=1&id=1428. Accessed
March 3, 2022. .
23. Li J, Wang AR, Chen XD, Zhang YX,
Pan H, Li SQ. Effect of hyperthermic
intraperitoneal chemotherapy in
combination with cytoreductive
surgery on the prognosis of patients
with colorectal cancer peritoneal
metastasis: a systematic review and
meta-analysis. World journal of
surgical oncology. 2022;20 (1):200.
24. Spiliotis J, Kalles V, Kyriazanos I,
Terra A, Prodromidou A, Raptis A, et
al. CRS and HIPEC in patients with
peritoneal metastasis secondary to
colorectal cancer: The small-bowel
PCI score as a predictor of survival.
Pleura and peritoneum. 2019;4
(4):20190018.
25. Frøysnes IS, Larsen SG, Spasojevic
M, Dueland S, Flatmark K.
Complete cytoreductive surgery
and hyperthermic intraperitoneal
chemotherapy for colorectal
peritoneal metastasis in Norway:
Prognostic factors and oncologic
outcome in a national patient cohort.
Journal of surgical oncology. 2016;114
(2):222-7.
26. Yonemura Y, Prabhu A, Sako S,
Ishibashi H, Hirano M, Mizumoto
A, et al. Effects of Cytoreductive
Surgery Combined with Perioperative
Chemotherapy on Long-Term
Survivals of Colorectal Cancer
Patients with Peritoneal Metastasis,
with Special Reference to the Involved
Peritoneal Sectors and Organs.
Gan to kagaku ryoho Cancer &
chemotherapy. 2019;46 (13):1917-21.
27. Torkzad MR, Casta N, Bergman A,
Ahlström H, Påhlman L, Mahteme
H. Comparison between MRI
and CT in prediction of peritoneal
carcinomatosis index (PCI) in
patients undergoing cytoreductive
surgery in relation to the experience
of the radiologist. Journal of surgical
oncology. 2015;111 (6):746-51.
28. Passot G, Dumont F, Goéré D, Arvieux
C, Rousset P, Regimbeau JM, et al.
Multicentre study of laparoscopic
or open assessment of the peritoneal
cancer index (BIG-RENAPE). The
British journal of surgery. 2018;105
(6):663-7.
29. Acs M, Dadras A, Blaj S, Leebmann
H, Piso P. Selection Criteria
for Cytoreductive Surgery and
Hyperthermic Intraperitoneal
Chemotherapy With Special Emphasis
on Laparoscopy as an Efficient Tool.
In vivo (Athens, Greece). 2022;36
(3):1367-74.
30. Alzahrani N, Ung L, Valle SJ,
Liauw W, Morris DL. Synchronous
liver resection with cytoreductive
surgery for the treatment of liver and
peritoneal metastases from colon
cancer: results from an Australian
centre. ANZ journal of surgery.
2017;87 (11):E167-e72.
31. Alzahrani NA, Valle SJ, Fisher OM,
Sugarbaker PH, Yonemura Y, Glehen
O, et al. Iterative cytoreductive
surgery with or without hyperthermic
intraperitoneal chemotherapy for
colorectal peritoneal metastases:
A multi-institutional experience.
Journal of surgical oncology. 2019;119
(3):336-46.
32. Nagata H, Ishihara S, Hata K, Murono
K, Kaneko M, Yasuda K, et al.
Survival and Prognostic Factors for
Metachronous Peritoneal Metastasis
in Patients with Colon Cancer.
Annals of surgical oncology. 2017;24
(5):1269-80.
33. van de Vlasakker VCJ, Lurvink
RJ, Cashin PH, Ceelen W, Deraco
M, Goéré D, et al. The impact of
PRODIGE 7 on the current worldwide
practice of CRS-HIPEC for colorectal
peritoneal metastases: A web-based
survey and 2021 statement by
Peritoneal Surface Oncology Group
International (PSOGI). European
journal of surgical oncology : the journal of the European Society of
Surgical Oncology and the British
Association of Surgical Oncology.
2021;47 (11):2888-92.
34. Quénet F, Elias D, Roca L,
Goéré D, Ghouti L, Pocard M,
et al. Cytoreductive surgery plus
hyperthermic intraperitoneal
chemotherapy versus cytoreductive
surgery alone for colorectal peritoneal
metastases (PRODIGE 7): a
multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology.
2021;22 (2):256-66.
35. Prabhu A, Brandl A, Wakama S,
Sako S, Ishibashi H, Mizumoto A,
et al. Effect of oxaliplatin-based
chemotherapy on chemosensitivity
in patients with peritoneal
metastasis from colorectal cancer
treated with cytoreductive surgery
and hyperthermic intraperitoneal
chemotherapy: proof-of-concept
study. BJS open. 2021;5 (2).
36. Pereira F, Serrano A, Manzanedo I,
Pérez-Viejo E, González-Moreno S,
González-Bayón L, et al. GECOPMMC:
phase IV randomized
clinical trial to evaluate the efficacy
of hyperthermic intraperitoneal
chemotherapy (HIPEC) with
mytomicin-C after complete surgical
cytoreduction in patients with colon
cancer peritoneal metastases. BMC
cancer. 2022;22 (1):536.
37. Kirstein MN, Root SA, Moore
MM, Wieman KM, Williams BW,
Jacobson PA, et al. Exposure-response
relationships for oxaliplatin-treated
colon cancer cells. Anti-cancer drugs.
2008;19 (1):37-44.
38. da Silva RG, Sugarbaker PH.
Analysis of prognostic factors in
seventy patients having a complete
cytoreduction plus perioperative
intraperitoneal chemotherapy for
carcinomatosis from colorectal
cancer. Journal of the American
College of Surgeons. 2006;203
(6):878-86.
39. Prabhu A, Brandl A, Wakama S,
Sako S, Ishibashi H, Mizumoto
A, et al. Retrospective Analysis of
Patients with Signet Ring Subtype
of Colorectal Cancer with Peritoneal
Metastasis Treated with CRS &
HIPEC. Cancers. 2020;12 (9).
40. Elias D, Gilly F, Boutitie F, Quenet
F, Bereder JM, Mansvelt B, et al.
Peritoneal colorectal carcinomatosis
treated with surgery and perioperative
intraperitoneal chemotherapy:
retrospective analysis of 523 patients
from a multicentric French study.
Journal of clinical oncology : official
journal of the American Society of
Clinical Oncology. 2010;28 (1):63-8.
41. Glehen O, Gilly FN, Boutitie F,
Bereder JM, Quenet F, Sideris L,
et al. Toward curative treatment
of peritoneal carcinomatosis from
nonovarian origin by cytoreductive
surgery combined with perioperative
intraperitoneal chemotherapy: a multiinstitutional
study of 1,290 patients.
Cancer. 2010;116 (24):5608-18.

Files

Share

How to cite

Statistics